Early corticosteroid treatment in 4 duchenne muscular dystrophy patients: 14-year follow-up

Muscle and Nerve

Volumn 45, Issue 6, 2012, Pages 796-802

  Merlini, Luciano ^a   Gennari, Monia ^b   Malaspina, Elisabetta ^b   Cecconi, Ilaria ^b   Armaroli, Annarita ^c   Gnudi, Saverio ^a   Talim, Beril ^d   Ferlini, Alessandra ^c   Cicognani, Alessandro ^b   Franzoni, Emilio ^b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Alternate day regimen; Corticosteroid therapy; Duchenne muscular dystrophy; Outcome; Prospective study

Indexed keywords

DEFLAZACORT; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; BONE AGE; CASE REPORT; CATARACT; CATCH UP GROWTH; CHILD; CLIMBING; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DELAYED PUBERTY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; GROWTH RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW DRUG DOSE; MALE; MOBILIZATION; OBESITY; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SHORT STATURE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WALKING; WEIGHT GAIN;

ADOLESCENT; ADRENAL CORTEX HORMONES; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PREDNISONE; PREGNENEDIONES; PROSPECTIVE STUDIES; PUBERTY, DELAYED; STROKE VOLUME; TREATMENT OUTCOME; WALKING;

EID: 84860896654     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23272     Document Type: Article

References (46)

1. Moxley RT III, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64: 13-20.
2. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
3. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol 2003; 3: 7.
4. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008: CD003725.
5. Moxley RTIII, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010; 25: 1116-1129.
6. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005; 84: 843-850.
7. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006; 16: 249-255.
8. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008; 18: 365-370.
9. Daftary AS, Crisanti M, Kalra M, Wong B, Amin R. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 2007; 119: e320-e324.
10. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68: 1607-1613.
11. Houde S, Filiatrault M, Fournier A, Dube J, D'Arcy S, Berube D, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008; 38: 200-206.
12. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT III, Griggs RC, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991; 41: 1874-1877.
13. Talim B, Malaguti C, Gnudi S, Politano L, Merlini L. Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord 2002; 12: 294-295.
14. Dubowitz V, Kinali M, Main M, Mercuri E, Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol 2002; 6: 153-159.
15. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 2002; 12( Suppl 1): S169-S174.
16. Carter GT, McDonald CM. Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy. Am J Phys Med Rehabil 2000; 79: 455-458.
17. Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003; 27: 222-227.
18. Angelini C, Bonifati M, Dubowitz V, Henriksson K, Malaspina E, Merlini L, et al. 47th ENMC International Workshop: Treatment of Muscular Dystrophy. 13-15 December 1996, Naarden, The Netherlands. Neuromuscul Disord 1997; 7: 261-267.
19. Rideau Y, Duport G, Delaubier A, Guillou C, Renardel-Irani A, Bach JR. Early treatment to preserve quality of locomotion for children with Duchenne muscular dystrophy. Semin Neurol 1995; 15: 9-17.
20. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23: 1344-1347.
21. Walton J. Disorders of voluntary muscle. Edinburgh, UK: Churchill Livingstone; 1988.
22. Merlini L, Mazzone ES, Solari A, Morandi L. Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 2002; 26: 64-70.
23. Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006; 29: 581-593.
24. Greulich WW, Pyle S. Radiographic atlas of skeletal development of the hand and wrist. California: Stanford University Press: Stanford University Press; 1950.
25. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9: 177-189.
26. Schara U, Mortier, Mortier W. Long-term steroid therapy in Duchenne muscular dystrophy-positive results versus side effects. J Clin Neuromuscul Dis 2001; 2: 179-183.
27. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138: 45-50.
28. Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12: 917-925.
29. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the muscular dystrophies. Muscle Nerve 1981; 4: 155-164.
30. Baydur A, Gilgoff I, Prentice W, Carlson M, Fischer DA. Decline in respiratory function and experience with long-term assisted ventilation in advanced Duchenne's muscular dystrophy. Chest 1990; 97: 884-889.
31. Corrado G, Lissoni A, Beretta S, Terenghi L, Tadeo G, Foglia-Manzillo G, et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 2002; 89: 838-841.
32. Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003; 91: 769-772.
33. Soderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 2007; 17: 919-928.
34. Quinlivan R, Shaw N, Bushby K. 170th ENMC International Workshop: Bone protection for corticosteroid treated Duchenne muscular dystrophy. 27-29 November 2009, Naarden, The Netherlands. Neuromuscul Disord 2010; 20: 761-769.
35. Conte JE. Manual of antibiotics and infectious diseases: treatment and prevention. Philadelphia: Lippincott, Williams, and Wilkins; 2002.
36. Merlini L, Granata C, Ballestrazzi A, Cornelio F, Tassoni P, Tugnoli S, et al. Growth hormone evaluation in Duchenne muscular dystrophy. Ital J Neurol Sci 1988; 9: 471-475.
37. Zatz M, Rapaport D, Vainzof M, Rocha JM, Pavanello Rde C, Colletto GM, et al. Relation between height and clinical course in Duchenne muscular dystrophy. Am J Med Genet 1988; 29: 405-410.
38. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 13-23.
39. Taylor RW, Jones IE, Williams SM, Goulding A. Body fat percentages measured by dual-energy X-ray absorptiometry corresponding to recently recommended body mass index cutoffs for overweight and obesity in children and adolescents aged 3-18 y. Am J Clin Nutr 2002; 76: 1416-1421.
40. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007; 36: 424-435.
41. Rahman MM, Hannan MA, Mondol BA, Bhoumick NB, Haque A. Prednisolone in Duchenne muscular dystrophy. Bangladesh Med Res Counc Bull 2001; 27: 38-42.
42. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320: 1592-1597.
43. Griggs RC, Moxley RT III, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991; 48: 383-388.
44. Backman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1995; 5: 233-241.
45. Beenakker EA, Fock JM, Van Tol MJ, Maurits NM, Koopman HM, Brouwer OF, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005; 62: 128-132.
46. Finkel R, Wong B, Bushby K, Reha A, Elfring GL, Miller LL, et al. P3.51 Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD). Neuromuscular Disorders 2010; 20: 656-657.